{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T06:53:55Z","timestamp":1785653635410,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Belgian Fonds National de la Recherche Scientifique (FNRS-FRS","award":["T.0189.16"],"award-info":[{"award-number":["T.0189.16"]}]},{"name":"Belgian Fonds National de la Recherche Scientifique (FNRS-FRS","award":["J.0018.17"],"award-info":[{"award-number":["J.0018.17"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ijantimicag.2019.11.005","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T11:15:45Z","timestamp":1574507745000},"page":"105848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor, afabicin desphosphono against different resistance phenotypes of Staphylococcus aureus in models of cultured phagocytic cells"],"prefix":"10.1016","volume":"55","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Peyrusson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Van Wessem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenna\u00eblle","family":"Dieppois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Van Bambeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Tulkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/1179916117703999","article-title":"An update on clinical burden, diagnostic tools, and therapeutic options of Staphylococcus aureus","volume":"10","author":"Reddy","year":"2017","journal-title":"Infect Dis (Auckl)"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0002","unstructured":"Tacconelli E, Magrini N. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. http:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic-resistant-bacteria\/en\/. Last updated: 27-2-2017 - last accessed: 3-2-2019"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0003","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/femsre\/fux007","article-title":"Antibiotic resistance in Staphylococcus aureus. Current status and future prospects","volume":"41","author":"Foster","year":"2017","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0004","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0005","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0006","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijmm.2013.11.011","article-title":"Staphylococcus aureus persistence in non-professional phagocytes","volume":"304","author":"Loffler","year":"2014","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0007","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/bph.13664","article-title":"Targeting the hard to reach: challenges and novel strategies in the treatment of intracellular bacterial infections","volume":"174","author":"Kamaruzzaman","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0008","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ijmm.2017.11.009","article-title":"Inside job: Staphylococcus aureus host-pathogen interactions","volume":"308","author":"Horn","year":"2018","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1172\/jci.insight.98216","article-title":"Targeting fundamental pathways to disrupt Staphylococcus aureus survival: clinical implications of recent discoveries","volume":"3","author":"Thomsen","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0010","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.01254-06","article-title":"In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis","volume":"51","author":"Karlowsky","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0011","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/AAC.00400-09","article-title":"AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity","volume":"53","author":"Karlowsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0012","unstructured":"Krishnamurthy NR, Lakshminarasimhan A, Subramanya HD. Aurigene Discovery Technologies Ltd, editor. Crystalline Structure of FABI from Burkholderia Pseudomallei. patent US 2017\/0088822 A1. 2017Mar 2017."},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01669-18","article-title":"Bone and joint tissues penetration of the Staphylococcus-selective antibiotic afabicin in patients undergoing elective hip replacement surgery","volume":"63","author":"Menetrey","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0014","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1128\/AAC.01411-12","article-title":"Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor","volume":"56","author":"Kaplan","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0015","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1128\/AAC.00535-16","article-title":"A pathogen-selective antibiotic minimizes disturbance to the microbiome","volume":"60","author":"Yao","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0016","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ejps.2013.08.019","article-title":"AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects","volume":"50","author":"Kaplan","year":"2013","journal-title":"Eur J Pharm Sci"},{"issue":"Suppl B","key":"10.1016\/j.ijantimicag.2019.11.005_bib0017","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jac\/20.suppl_B.47","article-title":"Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells","volume":"20","author":"Carlier","year":"1987","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl B","key":"10.1016\/j.ijantimicag.2019.11.005_bib0018","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jac\/26.suppl_B.27","article-title":"Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages","volume":"26","author":"Carlier","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0019","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/AAC.01723-09","article-title":"Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils","volume":"54","author":"Lemaire","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0020","series-title":"\"Bacterial Persistence\" (Molecular Biology Laboratory Protocols Series)","article-title":"In vitro models for the study of the intracellular activity of antibiotics","author":"Buyck","year":"2015"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0021","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/AAC.31.3.410","article-title":"Influence of conversion of penicillin G into a basic derivative on its accumulation and subcellular localization in cultured macrophages","volume":"31","author":"Renard","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0022","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/AAC.40.5.1225","article-title":"Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1","volume":"40","author":"Scorneaux","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0023","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1128\/AAC.47.3.1047-1051.2003","article-title":"Influence of p-glycoprotein inhibitors on accumulation of macrolides in j774 murine macrophages","volume":"47","author":"Seral","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0024","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1128\/AAC.00827-15","volume":"59","author":"Peyrusson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02245-17","article-title":"Cellular pharmacokinetics and intracellular activity of gepotidacin against Staphylococcus aureus isolates with different resistance phenotypes in models of cultured phagocytic cells","volume":"62","author":"Peyrusson","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0026","series-title":"24th informational supplement (MS100-S24): Clinical and Laboratory Standard Institute","article-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Anonymous","year":"2014"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0027","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1128\/AAC.01690-15","article-title":"Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent","volume":"59","author":"Ross","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0028","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/AAC.50.3.841-851.2006","article-title":"Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages","volume":"50","author":"Barcia-Macay","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0029","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF01964420","article-title":"Intracellular distribution and activity of antibiotics","volume":"10","author":"Tulkens","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/AAC.03684-14","article-title":"Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function","volume":"59","author":"Flanagan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0031","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/0006-2952(74)90174-9","article-title":"Commentary. Lysosomotropic agents","volume":"23","author":"de Duve","year":"1974","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0032","series-title":"4495, ASM Microbe, Boston, MA","article-title":"Efficacy of the FabI inhibitor afabicin for the treatment of Staphylococcus aureus-induced acute osteomyelitis in rabbit, abstr","author":"Barbier","year":"2016"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0033","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1128\/AAC.05119-14","article-title":"Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains","volume":"59","author":"Flamm","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1179\/1973947812Y.0000000061","article-title":"Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model","volume":"25","author":"Banevicius","year":"2013","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0035","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/jac\/dkl424","article-title":"Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus","volume":"58","author":"Barcia-Macay","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0036","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dks442","article-title":"Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin","volume":"68","author":"Melard","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0037","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/AAC.01135-08","article-title":"Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus","volume":"53","author":"Lemaire","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0038","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1179\/1973947812Y.0000000063","article-title":"In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics","volume":"25","author":"Kaplan","year":"2013","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.005_bib0039","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/jac\/dkp267","article-title":"Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines","volume":"64","author":"Lemaire","year":"2009","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791930319X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791930319X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:35:17Z","timestamp":1760376917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791930319X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S092485791930319X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.11.005","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor, afabicin desphosphono against different resistance phenotypes of Staphylococcus aureus in models of cultured phagocytic cells","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105848"}}